A placebo clinical remission rate of 10.4% at Week 44, which Abivax describes as the lowest reported to date in a Phase 3 ulcerative colitis maintenance trial, is the number that makes the company’s latest regulatory step worth scrutinizing. That figure is the floor against which obefazimod’s performance is measured, and it is an unusually low bar for a competitor to clear, which means the absolute remission rates, 50.8% for the 25 mg dose and 51.3% for the 50 mg dose, reflect a genuinely favorable operating environment for the drug. Against that backdrop, Abivax has now completed a positive pre-NDA interaction with the FDA, with the agency aligning on both the submission strategy and the planned content and format of the application for moderately to severely active ulcerative colitis in adults.
Pre-NDA meetings are procedural, but alignment on content and format is not trivial. The FDA’s feedback at this stage shapes whether a submission is accepted for filing or handed back with a refuse-to-file letter, a delay that can cost six months or more. That Abivax secured explicit alignment on both dimensions signals the dossier is structurally sound before the formal clock starts. The ABTECT maintenance data underpinning the NDA showed both doses hitting the primary endpoint at p less than 0.0001, with placebo-adjusted remission deltas of 39.3% and 40.3% respectively. Those are robust numbers in an indication where regulators have seen substantial evidence packages from multiple approved agents.
The competitive pressure is real. The ulcerative colitis market has absorbed several approvals in recent years, including risankizumab for UC in June 2024, meaning Abivax will need to demonstrate not just efficacy but a differentiated clinical profile to carve durable positioning. Obefazimod is an oral, once-daily small molecule with a mechanism targeting RNA splicing, which is mechanistically distinct from the biologics dominating the space. Whether that distinction translates into prescriber preference depends heavily on how the safety and durability data read in the full NDA package and, eventually, in the label.
The specific marker to track now is the FDA’s filing decision after submission, because a refuse-to-file action would reset the timeline materially and signal the dossier had gaps the pre-NDA interaction did not surface. A clean acceptance puts obefazimod on a standard review clock and makes the advisory committee outcome the next inflection point for the program.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
